This CPB is revised to state that (i) recombinant Von Willebrand factor (Vonvendi) is considered medically necessary for perioperative management of bleeding in adults with von Willebrand disease (ii) coagulation factor Xa (recombinant), inactivated-zhzo (Andexxa) is considered medically necessary for individuals treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding and (iii) idarucizumab (Praxbind) is considered medically necessary for individuals treated with dabigatran, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding or for emergency surgery or urgent procedures.